| scholarly article | Q13442814 |
| P356 | DOI | 10.1002/14651858.CD009008.PUB3 |
| P698 | PubMed publication ID | 26222249 |
| P50 | author | Christian Gluud | Q26265142 |
| Jørn Wetterslev | Q28037207 | ||
| David P Sonne | Q51716555 | ||
| Lars Hyldborg Lundstrøm | Q86576554 | ||
| Jeppe Bennekou Schroll | Q99559273 | ||
| Thomas Almdal | Q114398833 | ||
| Bianca Hemmingsen | Q114426371 | ||
| P2093 | author name string | Allan Vaag | |
| Søren S Lund | |||
| P2860 | cites work | Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinations | Q22241134 |
| Systematic Review: Comparative Effectiveness and Safety of Oral Medications for Type 2 Diabetes Mellitus | Q22241140 | ||
| Cardiovascular outcomes in trials of oral diabetes medications: a systematic review | Q22253058 | ||
| Industry sponsorship and research outcome | Q24202591 | ||
| Momordica charantia for type 2 diabetes mellitus | Q24240040 | ||
| Outcomes of patients who participate in randomized controlled trials compared to similar patients receiving similar interventions who do not participate | Q24242288 | ||
| Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus | Q24243196 | ||
| Rosiglitazone for type 2 diabetes mellitus | Q24243875 | ||
| Meglitinide analogues for type 2 diabetes mellitus | Q24245352 | ||
| Metformin monotherapy for type 2 diabetes mellitus | Q24246552 | ||
| Alpha-glucosidase inhibitors for type 2 diabetes mellitus | Q24246908 | ||
| Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis | Q24289436 | ||
| What is meant by intention to treat analysis? Survey of published randomised controlled trials | Q24647858 | ||
| Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study | Q24653790 | ||
| The case of the misleading funnel plot | Q24676535 | ||
| Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials | Q27860735 | ||
| Meta-analysis in clinical trials | Q27860779 | ||
| Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group | Q27860882 | ||
| GUIDE study: double-blind comparison of once-daily gliclazide MR and glimepiride in type 2 diabetic patients | Q28276621 | ||
| Vasodilatory effects of troglitazone improve blood pressure at rest and during mental stress in type 2 diabetes mellitus | Q28369239 | ||
| A Systematic Review and Meta-Analysis of Hypoglycemia and Cardiovascular Events: A comparison of glyburide with other secretagogues and with insulin | Q29397208 | ||
| Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group | Q29547282 | ||
| Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Provisional report of a WHO Consultation | Q29547453 | ||
| 10-year follow-up of intensive glucose control in type 2 diabetes | Q29615973 | ||
| Comparative effects of pioglitazone, glibenclamide, and voglibose on urinary endothelin-1 and albumin excretion in diabetes patients | Q44862770 | ||
| Regression of carotid atherosclerosis by control of postprandial hyperglycemia in type 2 diabetes mellitus. | Q44936558 | ||
| Comparison of tolbutamide and metformin in elderly diabetic patients | Q44942743 | ||
| Effects of pioglitazone and glimepiride on glycemic control and insulin sensitivity in Mexican patients with type 2 diabetes mellitus: A multicenter, randomized, double-blind, parallel-group trial | Q44953741 | ||
| Sustained effects of pioglitazone vs. glibenclamide on insulin sensitivity, glycaemic control, and lipid profiles in patients with Type 2 diabetes | Q44990830 | ||
| Effect of pioglitazone on carotid intima-media thickness and arterial stiffness in type 2 diabetic nephropathy patients | Q45064729 | ||
| Gliclazide modified release: results of a 2-year study in patients with type 2 diabetes | Q45102893 | ||
| Comparison of effect of pioglitazone with metformin or sulfonylurea (monotherapy and combination therapy) on postload glycemia and composite insulin sensitivity index during an oral glucose tolerance test in patients with type 2 diabetes | Q45242322 | ||
| Comparison of pioglitazone and gliclazide in sustaining glycemic control over 2 years in patients with type 2 diabetes | Q45285687 | ||
| Pioglitazone elicits long-term improvements in insulin sensitivity in patients with type 2 diabetes: comparisons with gliclazide-based regimens | Q45288350 | ||
| Comparison of continual insulin or secretagogue treatment in type 2 diabetic patients with alternate insulin-secretagogue administration | Q46096931 | ||
| Assessment on the Prevention of Progression by Rosiglitazone on Atherosclerosis in diabetes patients with Cardiovascular History (APPROACH): study design and baseline characteristics | Q46229084 | ||
| Rosiglitazone preserves islet beta-cell function of adult-onset latent autoimmune diabetes in 3 years follow-up study. | Q46247635 | ||
| Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial | Q46344895 | ||
| A long-term comparison of pioglitazone and gliclazide in patients with Type 2 diabetes mellitus: a randomized, double-blind, parallel-group comparison trial | Q46401187 | ||
| Comparison of gliclazide with insulin as initial treatment modality in newly diagnosed type 2 diabetes | Q46420603 | ||
| Cost-utility analyses of intensive blood glucose and tight blood pressure control in type 2 diabetes (UKPDS 72). | Q46440924 | ||
| Pioglitazone and heart failure: results from a controlled study in patients with type 2 diabetes mellitus and systolic dysfunction | Q46451214 | ||
| Pioglitazone decreases carotid intima-media thickness independently of glycemic control in patients with type 2 diabetes mellitus: results from a controlled randomized study | Q46481435 | ||
| Efficacy of glimepiride in Japanese type 2 diabetic subjects | Q46528450 | ||
| Comparison of metabolic effects of pioglitazone, metformin, and glimepiride over 1 year in Japanese patients with newly diagnosed Type 2 diabetes | Q46606036 | ||
| Pharmacological PPARgamma stimulation in contrast to beta cell stimulation results in an improvement in adiponectin and proinsulin intact levels and reduces intima media thickness in patients with type 2 diabetes | Q46683324 | ||
| Prolongation of Near-Normoglycemic Remission in Black NIDDM Subjects With Chronic Low-Dose Sulfonylurea Treatment | Q46880330 | ||
| Comparison of glycaemic control over 1 year with pioglitazone or gliclazide in patients with Type 2 diabetes | Q46955559 | ||
| Effect of pioglitazone on urinary liver-type fatty acid-binding protein concentrations in diabetes patients with microalbuminuria | Q46967291 | ||
| Long-term effects of pioglitazone versus gliclazide on hepatic and humoral coagulation factors in patients with type 2 diabetes | Q46973468 | ||
| Silymarin as an adjunct to glibenclamide therapy improves long-term and postprandial glycemic control and body mass index in type 2 diabetes | Q46987748 | ||
| Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials | Q47192223 | ||
| Postprandial plasma glucose excursions and cognitive functioning in aged type 2 diabetics. | Q48463721 | ||
| Sulfonylurea treatment prevents recurrence of hyperglycemia in obese African-American patients with a history of hyperglycemic crises | Q50963007 | ||
| Nateglinide provides tighter glycaemic control than glyburide in patients with Type 2 diabetes with prevalent postprandial hyperglycaemia | Q51382834 | ||
| Effects of pioglitazone hydrochloride on Japanese patients with type 2 diabetes mellitus | Q51471790 | ||
| Effects of insulin vs. glibenclamide in recently diagnosed patients with type 2 diabetes: a 4-year follow-up | Q51474263 | ||
| A one-year study comparing the efficacy and safety of rosiglitazone and glibenclamide in the treatment of type 2 diabetes | Q51483188 | ||
| A Diabetes Outcome Progression Trial (ADOPT): baseline characteristics of Type 2 diabetic patients in North America and Europe | Q51485169 | ||
| Long-term safety of pioglitazone versus glyburide in patients with recently diagnosed type 2 diabetes mellitus | Q51489163 | ||
| Diamicron MR once daily is effective and well tolerated in type 2 diabetes: a double-blind, randomized, multinational study | Q51553495 | ||
| Repaglinide versus glyburide: a one-year comparison trial | Q51562922 | ||
| A double-blind randomized comparison of meal-related glycemic control by repaglinide and glyburide in well-controlled type 2 diabetic patients | Q51563437 | ||
| A 1-year multicenter randomized double-blind comparison of repaglinide and glyburide for the treatment of type 2 diabetes. Dutch and German Repaglinide Study Group | Q51564465 | ||
| UKPDS 26: Sulphonylurea failure in non-insulin-dependent diabetic patients over six years. UK Prospective Diabetes Study (UKPDS) Group | Q51570043 | ||
| Clinical evaluation of glimepiride versus glyburide in NIDDM in a double-blind comparative study. Glimepiride/Glyburide Research Group | Q51579636 | ||
| A dose-response study of glimepiride in patients with NIDDM who have previously received sulfonylurea agents. The Glimepiride Protocol #201 Study Group | Q51580281 | ||
| Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group | Q51586347 | ||
| Insulin versus glipizide treatment in patients with non-insulin-dependent diabetes mellitus. Effects on blood pressure and glucose tolerance | Q51589041 | ||
| Antihyperglycaemic efficacy, response prediction and dose-response relations of treatment with metformin and sulphonylurea, alone and in primary combination | Q51592594 | ||
| Therapeutic comparison of metformin and sulfonylurea, alone and in various combinations. A double-blind controlled study | Q51593626 | ||
| Efficacy of 24-week monotherapy with acarbose, glibenclamide, or placebo in NIDDM patients. The Essen Study | Q51595095 | ||
| Long-term randomized placebo-controlled double-blind therapeutic comparison of glipizide and glyburide. Glycemic control and insulin secretion during 15 months | Q51597457 | ||
| Effect of rosiglitazone on progression of coronary atherosclerosis in patients with type 2 diabetes mellitus and coronary artery disease: the assessment on the prevention of progression by rosiglitazone on atherosclerosis in diabetes patients with c | Q38375360 | ||
| Oral hypoglycemic agents | Q38700011 | ||
| Global Burden of Diabetes, 1995–2025: Prevalence, numerical estimates, and projections | Q39474763 | ||
| Efficacy and safety of the once-daily human GLP-1 analogue, liraglutide, vs glibenclamide monotherapy in Japanese patients with type 2 diabetes | Q39895520 | ||
| Effect of pioglitazone on arteriosclerosis in comparison with that of glibenclamide | Q40426965 | ||
| Hydroxychloroquine in decompensated, treatment-refractory noninsulin-dependent diabetes mellitus. A new job for an old drug? | Q41943988 | ||
| Different effects of insulin and oral antidiabetic agents on glucose and energy metabolism in type 2 (non-insulin-dependent) diabetes mellitus | Q42491638 | ||
| Durability of efficacy and long-term safety profile of glyburide/metformin tablets in patients with type 2 diabetes mellitus: an open-label extension study | Q42685628 | ||
| Comparison of pioglitazone vs glyburide in early heart failure: insights from a randomized controlled study of patients with type 2 diabetes and mild cardiac disease | Q43014931 | ||
| Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: a 2-year study | Q43067803 | ||
| Comparison of insulin sensitivity, glucose sensitivity, and first phase insulin secretion in patients treated with repaglinide or gliclazide. | Q43111217 | ||
| Exenatide versus glibenclamide in patients with diabetes | Q43164036 | ||
| Efficacy and safety comparison between the DPP-4 inhibitor vildagliptin and the sulfonylurea gliclazide after two years of monotherapy in drug-naïve patients with type 2 diabetes | Q43286552 | ||
| Liver safety in patients with type 2 diabetes treated with pioglitazone: results from a 3-year, randomized, comparator-controlled study in the US. | Q43294072 | ||
| Cumulating evidence from randomized trials: Utilizing sequential monitoring boundaries for cumulative meta-analysis | Q43471039 | ||
| Importance of early insulin secretion: comparison of nateglinide and glyburide in previously diet-treated patients with type 2 diabetes | Q43618975 | ||
| Comparison between repaglinide and glipizide in Type 2 diabetes mellitus: a 1-year multicentre study | Q43687453 | ||
| Can trial sequential monitoring boundaries reduce spurious inferences from meta-analyses? | Q43707230 | ||
| Sulfonylurea inadequacy: efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the U.K. Prospective Diabetes Study (UKPDS 57). | Q43869405 | ||
| Prospective comparative study in NIDDM patients of metformin and glibenclamide with special reference to lipid profiles | Q43945425 | ||
| Metformin decreases platelet superoxide anion production in diabetic patients | Q43982807 | ||
| Simultaneous glyburide/metformin therapy is superior to component monotherapy as an initial pharmacological treatment for type 2 diabetes. | Q44016357 | ||
| Repaglinide versus glibenclamide treatment of Type 2 diabetes during Ramadan fasting | Q44088446 | ||
| A diabetes outcome progression trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes | Q44155654 | ||
| A comparison of the effects of rosiglitazone and glyburide on cardiovascular function and glycemic control in patients with type 2 diabetes | Q44195340 | ||
| Heterogeneity of non-insulin-dependent diabetes expressed as variability in insulin sensitivity, beta-cell function and cardiovascular risk profile. | Q44272873 | ||
| Rosiglitazone reduces urinary albumin excretion in type II diabetes | Q44305174 | ||
| Metabolic Effects of Mealtime Insulin Lispro in Comparison to Glibenclamide in Early Type 2 Diabetes | Q44440952 | ||
| Comparison between repaglinide and glimepiride in patients with type 2 diabetes mellitus: a one-year, randomized, double-blind assessment of metabolic parameters and cardiovascular risk factors | Q44442589 | ||
| Combination treatment with metformin and glibenclamide versus single-drug therapies in type 2 diabetes mellitus: a randomized, double-blind, comparative study | Q44517908 | ||
| Beneficial effects of insulin versus sulphonylurea on insulin secretion and metabolic control in recently diagnosed type 2 diabetic patients | Q44526955 | ||
| Efficacy of glyburide/metformin tablets compared with initial monotherapy in type 2 diabetes | Q44547506 | ||
| Is acarbose equivalent to tolbutamide as first treatment for newly diagnosed type 2 diabetes in general practice? A randomised controlled trial | Q44704733 | ||
| Favorable effects of pioglitazone and metformin compared with gliclazide on lipoprotein subfractions in overweight patients with early type 2 diabetes | Q44705128 | ||
| Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study | Q44802551 | ||
| A randomized crossover study of sulphonylurea and insulin treatment in patients with type 2 diabetes poorly controlled on dietary therapy | Q51620175 | ||
| Long-term comparison of oral hypoglycemic agents in diabetic retinopathy. Gliclazide vs. other sulfonylureas | Q51624978 | ||
| Glyburide or insulin for metabolic control in non-insulin-dependent diabetes mellitus. A randomized, double-blind study | Q51626419 | ||
| Methods for combining randomized clinical trials: strengths and limitations | Q52599212 | ||
| Overcoming the limitations of current meta-analysis of randomised controlled trials | Q52900034 | ||
| Glipizide versus tolbutamide in maturity-onset diabetes, an open comparative study | Q54170682 | ||
| A long-term, randomized, comparative study of insulin versus sulfonylurea therapy in type 2 diabetes | Q54195480 | ||
| Carbutamide in diabetes: report of a long-term trial, with special reference to late failures. | Q55689543 | ||
| Investigating and Dealing with Publication and Other Biases | Q56527888 | ||
| A Coefficient of Agreement for Nominal Scales | Q57167717 | ||
| Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) | Q57412648 | ||
| Quality of life in type 2 diabetic patients is affected by complications but not by intensive policies to improve blood glucose or blood pressure control (UKPDS 37). U.K. Prospective Diabetes Study Group | Q58678827 | ||
| Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. National Diabetes Data Group | Q66972631 | ||
| Efficacy of glibenclamide in maturity-onset diabetics as maintenance therapy | Q67246427 | ||
| [The influence of various sulphonylurea derivatives on the oral glucose-tolerance tests in healthy subjects and obese and maturity-onset diabetics (author's transl)] | Q67289048 | ||
| The fiftieth anniversary of hypoglycaemic sulphonamides. How did the mother compound work? | Q67593927 | ||
| A study of the effects of hypoglycemia agents on vascular complications in patients with adult-onset diabetes. VI. Supplementary report on nonfatal events in patients treated with tolbutamide | Q67864944 | ||
| Lack of effect of gliclazide on early diabetic nephropathy and retinopathy: a two-year controlled study | Q68950036 | ||
| Medication compliance in non-insulin-dependent diabetes: a randomized comparison of chlorpropamide and insulin | Q69895946 | ||
| The effects of gliclazide in diabetes: a comparison with tolbutamide | Q70247345 | ||
| Effect of chlorpropamide and gliclazide on plasminogen activator activity in vascular walls in patients with maturity onset diabetes | Q70495821 | ||
| Hyponatremia due to chlorpropamide. A syndrome resembling inappropriate secretion of antidiuretic hormone | Q71406521 | ||
| NIDDM: a rapid progressive disease. Results from a long-term, randomised, comparative study of insulin or sulphonylurea treatment | Q71876390 | ||
| Thrombin-induced platelet aggregation, phosphoinositide metabolism and protein phosphorylation in NIDDM patients treated by diet, sulphonylurea or insulin | Q72717830 | ||
| Metabolic effects of chronic glipizide gastrointestinal therapeutic system on serum glucose, insulin secretion, insulin sensitivity, and hepatic insulin extraction in glucose-tolerant, first-degree relatives of African American patients with type 2 | Q73420521 | ||
| The blood glucose lowering effects of exercise and glibenclamide in patients with Type 2 diabetes mellitus | Q74450253 | ||
| Diabetic neuropathy in elderly Type 2 diabetic patients: effects of insulin treatment | Q77700927 | ||
| Effects of gliclazide versus metformin on the clinical profile and lipid peroxidation markers in type 2 diabetes | Q78044125 | ||
| THE LONG-TERM EFFECT OF TOLBUTAMIDE ON GLUCOSE TOLERANCE IN ADULT, ASYMPTOMATIC, LATENT DIABETICS | Q78466478 | ||
| Safety of type 2 diabetes treatment with repaglinide compared with glibenclamide in elderly people: A randomized, open-label, two-period, cross-over trial | Q80012595 | ||
| Cardiovascular safety of rosiglitazone | Q80489425 | ||
| Effect of Repaglinide Versus Glyburide on Postprandial Glucose and Insulin Values in Elderly Patients with Type 2 Diabetes | Q82980031 | ||
| Comparison of diabetic control in type 2 (non-insulin dependent) diabetic patients treated with different sulphonylureas | Q93558538 | ||
| Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus | Q29616284 | ||
| Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses | Q29619185 | ||
| Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses? | Q29619328 | ||
| Interaction revisited: the difference between two estimates | Q29619619 | ||
| Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy | Q29620534 | ||
| Meglitinide analogues in the treatment of type 2 diabetes mellitus | Q30630393 | ||
| Chinese herbal medicines for type 2 diabetes mellitus | Q31097067 | ||
| Concentration of the complement activation product, acylation-stimulating protein, is related to C-reactive protein in patients with type 2 diabetes | Q32076220 | ||
| Uncertainty method improved on best-worst case analysis in a binary meta-analysis | Q33214758 | ||
| Influence of glucose control and improvement of insulin resistance on microvascular blood flow and endothelial function in patients with diabetes mellitus type 2. | Q33224649 | ||
| Apparently conclusive meta-analyses may be inconclusive--Trial sequential analysis adjustment of random error risk due to repetitive testing of accumulating data in apparently conclusive neonatal meta-analyses | Q33372680 | ||
| Comparison of acarbose and gliclazide as first-line agents in patients with type 2 diabetes | Q33423005 | ||
| Multicenter, placebo-controlled trial comparing acarbose (BAY g 5421) with placebo, tolbutamide, and tolbutamide-plus-acarbose in non-insulin-dependent diabetes mellitus | Q33484138 | ||
| The efficacy and safety of miglitol therapy compared with glibenclamide in patients with NIDDM inadequately controlled by diet alone | Q33486737 | ||
| Fifty-two-week, randomized, multicenter trial to compare the safety and efficacy of the novel glucagon-like peptide-1 analog liraglutide vs glibenclamide in patients with type 2 diabetes | Q33585560 | ||
| Randomized controlled trial of single-agent glimepiride and pioglitazone in Japanese patients with type 2 diabetes: A comparative study | Q33603557 | ||
| Addressing missing data in clinical trials | Q33795600 | ||
| A randomized trial of therapies for type 2 diabetes and coronary artery disease | Q33827504 | ||
| Comparative tolerability of sulphonylureas in diabetes mellitus | Q33903076 | ||
| Patient-reported outcomes following treatment with the human GLP-1 analogue liraglutide or glimepiride in monotherapy: results from a randomized controlled trial in patients with type 2 diabetes. | Q33982482 | ||
| Experience of malignancies with oral glucose-lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical t | Q34023560 | ||
| The number of patients and events required to limit the risk of overestimation of intervention effects in meta-analysis--a simulation study | Q34058272 | ||
| Cardiovascular effects of sulphonylureas: role of K(ATP) channels | Q34163342 | ||
| Insulinotropic meglitinide analogues | Q34453173 | ||
| Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial | Q34572519 | ||
| Myocardial reperfusion injury. | Q34687124 | ||
| Glipizide versus tolbutamide, an open trial. Effects on insulin secretory patterns and glucose concentrations | Q34714242 | ||
| Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial | Q34766176 | ||
| Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes | Q34862358 | ||
| Liraglutide, a once-daily human glucagon-like peptide 1 analogue, provides sustained improvements in glycaemic control and weight for 2 years as monotherapy compared with glimepiride in patients with type 2 diabetes | Q34886311 | ||
| Renal function in type 2 diabetes with rosiglitazone, metformin, and glyburide monotherapy | Q34926845 | ||
| Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial | Q34985342 | ||
| Beta-cell dysfunction and insulin resistance in type 2 diabetes: role of metabolic and genetic abnormalities | Q34996991 | ||
| Bias in clinical intervention research. | Q36380552 | ||
| Biologic actions and therapeutic potential of the proglucagon-derived peptides | Q36575421 | ||
| Clinical evaluation of glimepiride (HOE490) in NIDDM, including a double blind comparative study versus gliclazide | Q36787255 | ||
| P921 | main subject | type 2 diabetes | Q3025883 |
| P577 | publication date | 2015-07-29 | |
| P1433 | published in | Cochrane Database of Systematic Reviews | Q15750361 |
| P1476 | title | Sulphonylurea monotherapy for patients with type 2 diabetes mellitus |
Search more.